The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1301
Antiviral Drugs for Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Antiviral drugs are an important adjunct to influenza vaccination and can be used for treatment of patients with influenza within 2 days of the onset of illness and for chemoprophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination. Patients who are immunocompromised or immunosuppressed, have pulmonary disease, are elderly or are healthcare workers may also be appropriate candidates for chemoprophylaxis.

NEURAMINIDASE INHIBITORS — Chemoprophylaxis – Oseltamivir (Tamiflu – Roche), which is taken orally, and zanamivir (Relenza – GSK), which is inhaled, are about 70-90% effective for prophylaxis after exposure to influenza A or B.1 When indicated they should be started within 48 hours after a household exposure or other close contact with an influenza virus-infected person.

Treatment – In clinical trials, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Antiviral Drugs for Influenza
Article code: 1301b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian